Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
93.82
-0.58 (-0.61%)
At close: Jun 27, 2025, 4:00 PM
93.40
-0.42 (-0.45%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Verona Pharma Revenue
Verona Pharma had revenue of $76.26M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $118.54M. In the year 2024, Verona Pharma had annual revenue of $42.28M.
Revenue (ttm)
$118.54M
Revenue Growth
n/a
P/S Ratio
63.35
Revenue / Employee
$567,153
Employees
209
Market Cap
8.55B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VRNA News
- 18 days ago - Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
- 5 weeks ago - Verona Pharma Announces June 2025 Investor Conference Participation - GlobeNewsWire
- 7 weeks ago - Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 - GlobeNewsWire
- 2 months ago - Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster - Seeking Alpha
- 2 months ago - Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical - Seeking Alpha
- 3 months ago - Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS - GlobeNewsWire